Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.verified

LXRX

Price:

$0.827

Market Cap:

$298.95M

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.[Read more]

Industry

Biotechnology

IPO Date

2000-04-07

Stock Exchange

NASDAQ

Ticker

LXRX

The Enterprise Value as of December 2024 (TTM) for Lexicon Pharmaceuticals, Inc. (LXRX) is 365.60M

According to Lexicon Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 365.60M. This represents a change of -35.12% compared to the average of 563.51M of the last 4 quarters.

Lexicon Pharmaceuticals, Inc. (LXRX) Historical Enterprise Value (quarterly & annually)

How has LXRX Enterprise Value performed in the past?

The mean historical Enterprise Value of Lexicon Pharmaceuticals, Inc. over the last ten years is 634.60M. The current 365.60M Enterprise Value has changed 5.66% with respect to the historical average. Over the past ten years (40 quarters), LXRX's Enterprise Value was at its highest in in the June 2017 quarter at 1.80B. The Enterprise Value was at its lowest in in the September 2020 quarter at 123.15M.

Quarterly (TTM)
Annual

Average

634.60M

Median

581.53M

Minimum

254.66M

Maximum

1.19B

Lexicon Pharmaceuticals, Inc. (LXRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Lexicon Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 278.25%

Maximum Annual Enterprise Value = 1.19B

Minimum Annual Increase = -68.81%

Minimum Annual Enterprise Value = 254.66M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023421.93M29.62%
2022325.50M-36.44%
2021512.08M92.79%
2020265.62M-59.20%
2019650.98M-17.29%
2018787.09M-19.15%
2017973.49M-18.29%
20161.19B23.68%
2015963.25M278.25%
2014254.66M-68.81%

Lexicon Pharmaceuticals, Inc. (LXRX) Average Enterprise Value

How has LXRX Enterprise Value performed in the past?

The current Enterprise Value of Lexicon Pharmaceuticals, Inc. (LXRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

419.84M

5-year avg

435.22M

10-year avg

634.60M

Lexicon Pharmaceuticals, Inc. (LXRX) Enterprise Value vs. Peers

How is LXRX’s Enterprise Value compared to its peers?

Lexicon Pharmaceuticals, Inc.’s Enterprise Value is less than BioLineRx Ltd. (0), greater than Ardelyx, Inc. (44.33M), less than Seres Therapeutics, Inc. (1.14B), greater than ImmunityBio, Inc. (191.57M), less than eFFECTOR Therapeutics, Inc. (2.58B), greater than X4 Pharmaceuticals, Inc. (4.74M), greater than Elevation Oncology, Inc. (79.21M), greater than Mereo BioPharma Group plc (16.72M), less than Hepion Pharmaceuticals, Inc. (445.16M), greater than Galera Therapeutics, Inc. (4.20M), greater than Terns Pharmaceuticals, Inc. (-6768842.00), greater than Day One Biopharmaceuticals, Inc. (234.86M), less than HOOKIPA Pharma Inc. (859.59M), greater than Enveric Biosciences, Inc. (-37325309.00), greater than CohBar, Inc. (40.99K), greater than Ocean Biomedical, Inc. (-4359535.00), greater than AVROBIO, Inc. (34.40M), greater than null (-85302404.00),

Build a custom stock screener for Lexicon Pharmaceuticals, Inc. (LXRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lexicon Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lexicon Pharmaceuticals, Inc. (LXRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lexicon Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Lexicon Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Lexicon Pharmaceuticals, Inc. (LXRX)?

What is the 3-year average Enterprise Value for Lexicon Pharmaceuticals, Inc. (LXRX)?

What is the 5-year average Enterprise Value for Lexicon Pharmaceuticals, Inc. (LXRX)?

How does the current Enterprise Value for Lexicon Pharmaceuticals, Inc. (LXRX) compare to its historical average?